Pediatrics, University of California San Francisco, San Francisco, California, USA
Pediatrics, University of California San Francisco, San Francisco, California, USA.
BMJ Open Qual. 2022 Mar;11(1). doi: 10.1136/bmjoq-2021-001616.
In paediatric patients with acute gastroenteritis (AGE), ondansetron use decreases the need for intravenous fluids, reduces hospitalisations and shortens illness duration. Oral rehydration is also known to have excellent outcomes for mild to moderate dehydration secondary to AGE. Although these interventions are recommended in guidelines from international professional societies, baseline data at our clinic showed that <2% of these patients were offered ondansetron, and that few patients received appropriately detailed rehydration instructions. Therefore, we engaged residents and fellows as teachers and leaders in our university clinic's quality improvement programme to promote evidence-based practice for paediatric AGE. Our gap analysis identified opportunities for interventions including educating paediatricians and paediatrics residents on the safety and utility of the medication. We created standardised oral rehydration after-visit instructions and implemented a trainee-led educational approach that encouraged appropriate medication use. We used a follow-up survey to uncover provider concerns and tailor future interventions. The process metrics included: proportion of paediatric patients appropriately treated with ondansetron (goal of 80%), and proportion of patients given appropriate oral rehydration instructions. The outcome metric was 7-day representation rates. To achieve sustainability, we restructured our process to have senior residents take ownership of teaching and data collection. Trainee-driven interventions increased ondansetron prescription rates to a median of 66.6%. Patients prescribed ondansetron were less likely to represent to care, although representation rate was low overall. Postintervention data suggests that prescription rates decreased without continued interventions and additional systems redesign may help sustain impact.
在患有急性肠胃炎(AGE)的儿科患者中,昂丹司琼的使用减少了静脉补液的需求,降低了住院率并缩短了病程。口服补液也被认为对轻度至中度 AGE 引起的脱水有极好的效果。尽管这些干预措施在国际专业协会的指南中得到推荐,但我们诊所的基线数据显示,只有不到 2%的患者被建议使用昂丹司琼,而且很少有患者得到了适当详细的补液指导。因此,我们让住院医生和研究员作为教师和领导者,参与到我们大学诊所的质量改进计划中,以促进儿科 AGE 的循证实践。我们的差距分析确定了可以进行干预的机会,包括向儿科医生和儿科住院医生教育该药物的安全性和实用性。我们创建了标准化的门诊后口服补液指导,并实施了以学员为主导的教育方法,鼓励适当使用药物。我们使用后续调查来发现提供者的关注点,并调整未来的干预措施。过程指标包括:适当使用昂丹司琼治疗的儿科患者比例(目标为 80%),以及给予适当口服补液指导的患者比例。结果指标是 7 天就诊率。为了实现可持续性,我们对流程进行了重组,让高级住院医生负责教学和数据收集。学员驱动的干预措施将昂丹司琼的处方率提高到中位数 66.6%。使用昂丹司琼的患者就诊的可能性较低,但总体就诊率较低。干预后的数据表明,处方率在没有持续干预的情况下有所下降,可能需要进一步的系统重新设计来维持效果。